Shares in Proteome were trading up 12% at
The study was published in 'Alzheimers & Dementia:
Using data from three international studies, it took blood samples from a total of 1,148 individuals and analysed them for 26 proteins that had previously shown a connection to Alzheimer's.
From this study, the company identified 10 proteins capable of predicting whether patients with mild cognitive impairment would develop Alzheimer's within a year, which it said has an accuracy of 87%.
Proteome said that it was selecting commercial partners to combine these protein biomarkers in a blood test for the global market.
The company said the study was a "major advance" in developing a blood test for the disease, and such a test would be easier and less expensive than using brain imaging or cerebrospinal fluid.
Most Popular Stories
- Hernandez lawyer: Pats Records Dispute Resolved
- Congress Leaving Town as Deadlines Loom
- Oregon Voters to Decide on Recreational Pot
- 4th Circuit Upholds Obamacare Subsidies
- Fiat, Renault Strike Deal on New Light Vehicle
- Oregon to Vote on Recreational Marijuana
- Senate, House Locking Horns on Border Funds
- Jeter, Bauer Give Fox a Strong Week in TV Ratings
- LinkedIn to Buy Ad Tech Company Bizo for $175 Million
- A's Agree to 10-Year Lease to Stay in Oakland